16 cases of affective disorder were studied. 8 patients received carbamazepinc and 8 received either chlorpromazine or imipramiiie. Ratings were carried out on the Hamilton Rating Scale for Depresion, Bech Rafaelsen Mania Rating scale and a side-effects sysmtom check list. Garbamazepine was found to be an effective treatment for affective disorders, possessing both anti-manic as well as anti-depressant properties.
The fact that carbamazepine an iminodibenzyl derivative and an established antiepileptic agent, may be useful in psychiatric disorders was noted many years ago (Marjerrison et al,. 1968 ). Most of the early leports were of uncontrolled clinical trials. The psychotropic effects of carbamazepine have, since, been studied extensively (Pryse-Phillips & Jeavens, 1970; Rodin et al., 1974) . Dalby (1975) in a review of 40 reports found that 50% of 2500 patients with epilepsy improved psychiatrically when given carbamazepine. The phasic disorders of epilepsy resembling functional psychiatric syndromes, especially manicdepressive illness and schizophreniform psychoses, often show a dramatic response to carbamazepine. Sometimes this response is without a concomitant reduction in the frequency of seizures (Dalby, 1975) . Recent investigations, therefoie, have been directed towards delineation of the possible tole of carbamazepine in the management of affective disorders. Investigators, mainly from Japan and the U. S. A. have suggested that carbamazepine may be effective in manic depressive illness (Folks et al., 1982; Ballenger & Post, 1980; Okuma et al., 1979; and Takezaki & Hanaoka, 1971) . Okuma and associates (1979) compared the antimanic efficacy of carbamazepine and chlorpromazine. They reported an overall improvement of the patients on Garbamazepine to be about 70%.
Recent teports have also shown that carbamazepine maybe effective in affective disorders in a synergistic fashion with lithium. Forrest (1982) , in a case report, described the case of a 45 years old man with Right Hemisphrectomy (done for intractable epilepsy) who developed a rapid cycling bipolar illness. This responded well only when carbamazepine was added to lithium. A similar report of synergism between carbamazepine and lithium has been described by Lipinski et al (1982) . Ballenger and Post (1976, 1978) have postulated a kindling model of affective psychoses, wherein cumulative bioelectrical changes, particularly in the limbic area, secondary to repeated biochemical or psychological stresses, could result in abnormal limbic neuronal sensitization and major psychiatric disturbances.
Garbamazepine has been demonstrated to suppress after discharges (Koella et al., 1975) Bunt.cy, 1982) . Thetefore, it is «:-.><;nii.iI IO develop alternatives io liihiiun carbonate. Cnrbama/.epine would .'-ecu to fill litis need. However, precntly the. e is an urgent need lo evaluate carbamazepine in a larger population of patients to find out as to which pilient-respond IO carbamiziph.e (CBZ: and whctlici it is effective in patients who do rot respond to lithium. Its synergistic and efficacious combination with Lithium also needs to be looked into. Hence, keeping in view the alveuce of any Italian reports on (tiis topic, we decided to carry out a pilot invent iga tio t iiro ihe io!e ofcarbamazipine in M.mic-Depi e sue Illness.
MATERIA!, AND METHODS
An opci' study mi the effects of Carb uuazepino w'ts planne I. Patients diaguo ed as eithct M i jo; Deptcssive Disorder or Bipolar I)i>order according io DSM-III were included into ihe siudy. Paiicits with depletion were then startel on cithc Imipr.mhec (IMI) or C it bamazepii.c V CBZ: according to a randomization M'hedttle.
Sijnilaily, manic patients were started randomally either on chlnrpi omazine (CPZ; or C.'BZ The affective states were moui'o:ed throughout tie studv period .'on days 0, 3, 14, 21 and 28 of four weeks. Patients ov. IMI wc e given 7.1 jug. IMI pet day to-3 day*, which was then incici-ed ;o 150 mg. for 14 days. If at ihe end of day 14 the.e was less than 70",, impt oveme-it on the Hamihoii Rating Scale for Depression, then the dose was ii ctc.^cd to 200 mg./day.
Patients on CPZ were given 600 mg. of CPZ for 3 days which was then increased to 1000 jug. till day 14. If there was less than 70% improvement on the BechRafaelsen Mania Rating Scale then the doc was increased to 1300 mg/day. All patients on CBZ were given 600 mg. of CBZ for 3 days. Doe was then increased to 1000 mg/day till day '4. If there was less than 70% ijnpiovemeiit then the dose was increased to 1600 mg/day. The ratings were carried out on the following instruments: (l) The Bcch-Rafaels.cn Mania Rating Scale, (ii) Hamilton Rating Scale for Depression, (iii 1 ) Side-effect symptom Check-list, (iv) Clinical Global Implosion Schedule. All patients were between 18 and 55 years of age. Pregnancy and evidence of any major physical illv.es were exclusion criteria. All patients wete given thorough clinical physical examination a7id were ime-aiga ted, including complete blood count, plate'e. count and ECG.
OBSERVATION'S AND RESULTS
This is a report of 16 Cases, of which 8 were on Carbamazepine and 8 on chlorpromazine or Imipramine (depending iipoi the clinical state). Of the 8 patients on CBZ, 6 showed moderate to mirked improvement in their clinical status. Oi.e paticai (B. L.) showed only about 50% improvement while another showed m'rked side effects of CBZ which resulted in a discontinuation of her trial. This young female ^37 yrs. old) was diagnosed as crc of recurrent bipolar affective disorder, being in the depressed phase at ibe start of trial. She was without any side elfec's tilt d. y 5, i. e. ore day after ii.ocae of do e from 600 mg. of CBZ 'o 1000 mg. From day 5 she developed nan-en. dizzne-s ;! nd vomiting. On days 6 at.d 7 she was given lower doe. (600 mg'day of CBZ but there was no leohtiio:; in thee side effects. Patient was, theiefote, found quile dehydrated o-i clay 8, when it was decided that the drug had to be discontinued and patient was managed on I. V. fluids for her immediate problems. Scores on HRSD by ead of wk. 1 had i:ot shown any significant alteration. Ratings oa the B-R Mania Rat big Scale and HRS for Depression showed that the maximum improvement occurred by day 14 of the study period. A similar assessment of patieits on either CPZ or IMI shows that of the 8 patients who completed the clinical irial. only 2 showed mild to moderate improvement.
One of these 2 was a patient of major Depressive disorder, 39 yrs. old, who manifested only less than 50% improvement on 200 mg/day of IMI. This patient was also quite troubled by mainly dizziness and postural hypotension. Physical examination and laboratory investigations did not reveil any physical abnormality.
Notie of the patient* on .:iiy modality of treitment showed any haematologic or cardiac abnormalities during the trial period.
The major side effects observed with CPZ or IMI were not of such an intensity so as to warrant a discontinuation in ;,i y patient. Amongst the side effects of Carbamazepine-dizzi- No. of Patients ness and nausea were the ones most commonly observed. Usual time of onset of side-effects was from day 4 onwards and usually disappeared on the same dose after a i;ap of about 2-5 days. 3 Patients also developed mild ataxia and tremors which were transicat. 2 patients complained of blurred vision and on examination aho had definite diplopia. This side-effect was aho transient in both subjects. Drowsiness, slurred speech, clumsiness and vomiting were tio'ed in 1 patient e.ich. No.ie of the patients deve'oped any skin rash, congnitive impairment, confusion-weakness and aching ill legs, paivc-.lhcs.ias or cardiac arrhythmias (being the other commonly reported side-effects of CBZ). One patient developed a doubtful postural hypotension, noted only on otie occasion at night by the resident on emergency duty. Subsequent monitoring next morning or thereafter did not reveal any .such finding. In the night there was a systolic difference of 24 mm. of Hg and a diastolic difference of 10 mm. of Hg. No patient on GPZ manifested any extrapyramidal side effects and drowsiness/ sedation was uncommon. Rarely, patients on GBZ were needed to be given concomitant medication, the side effects being managed usually on the same dose or a slight-transient reduction of the same. Most patients on GPZ needed antiparkinsonian medication. In this study 'marked' improvement was usually attributed to patients manifesting over 90% reduction in ratings on the scales, irrespective of the side-effects. A patient manifesting over 70% improvement was considered as 'moderately' improved.
DISCUSSION
This report is the first from our country regarding the efficacy of Carbamazepine in Affective Disorders. This is an ongoing study and an initial, pilot investigation at our centre where in we are comparing the efficacy of GBZ with established psychotropic agents (GPZ & IMI) in an open study design. The initial impression given by this trial indicates GBZ to be at least as effective as IMI/GPZ in Depression/Mania. Prophylactic effects were not studied in this trial. Side effects were not found to be limiting except in one out of 8 patients.
Garbamazepine has a ring-like structure similar to that imipramine and it has been in use since the late 1950s as the principal treitme.it for trigermin.il neuralgia and since 1962 for psychomotor epilepsy. Its side effects which are most frequently reported rarely necessitate discontinuation of treatment (Parsonage, 1975) . Side effects are leportcd to be minimized if the increase in dosage is slow/gradual and the serum levels remain below 12.0 Ug/ml. This obseiv.ition is quite consistent with our own observations where in we usually noted transient side effects to appear from day 4 onwards : our study design having determined that after day 3 the clo-e of GBZ was to be increased from 600 mg/day to 1000 mg/day stabilization at the higher dose, and therefore an expected stabilization of serum levels were enough to dispense with the side-effects. Ballenger and Post (1980) reported that their patients improved on GBZ usually by the 1st wtvk of treatment and the antimanic effects continued throughout the 3 wk trial. We have a similar experience, when we notice that our patients usually improved by day 14 to quite an extent and only 2 patients required the dose of GBZ to be increased from 1000 to 1600 mg/day. Improvement, once occurred, continued to be manifest throughout the study period. Folks et al. (1982) reported that GBZ may have antimanic as well as anti-depressant properties. Our study, although open in nature, also seems to suggest a similar finding. The other conclusions drawn by these authors viz., (a) GBZ may be effective in some lithium non-reponders (b) GBZ and Li or GBZ and antidepressants may have synergistic efficacy and that (c) GBZ may be especially useful in GNS disordered patients with affective syndromes, could not obviously be tested owing to the study design employed in our study. Doubtless, these observations are important areas for future investigation. More over, it would be surely desirable to assess the prophylactic efficacy of GBZ in recurrent affective disorders. Reports suggesting the importance of GBZ in rapid cyclers need to be substantiated too. We have already planned a crossover study using GBZ and Lithium. GBZ, with its antimanic properties-may B. B. SETHI it at. be a useful antidepressant in the fact that it would l>c free to the problem of induction of mania in bipolar depressed patients, a hazard reported with other antidepressant medication (Wehr & Goodwin, 1979) . Thus, dually, we feel that well-coaiioiled studies are surely needed in this area and these would throw additional light into the management and aotiological understanding of Allective disorders.
